AIxCrypto Holdings Launches AI Evaluation Platform "Agentir" to Enhance Blockchain Integration
- AIxCrypto Holdings launched the "Agentir" platform to evaluate AI agents, bridging Web2 and Web3 technologies.
- The company reported a 336% growth in user engagement, reaching over 4.8 million registered wallet addresses.
- Hub S2 offers users modular tools for AI agent ownership, enhancing access to AI technologies within the ecosystem.
AIxCrypto Holdings Expands Ecosystem with Launch of Innovative AI Evaluation Platform
AIxCrypto Inc. (NASDAQ: AIXC) propels forward in the burgeoning intersection of artificial intelligence (AI) and blockchain technology with its latest announcement regarding the expansion of its ecosystem. This crucial initiative centers around the introduction of "Agentir," a specialized environment dedicated to the performance evaluation of AI agents. This platform not only reinforces AIxC's commitment to fostering innovation in synthetic intelligence but also aligns with the company's broader goal of bridging Web2 and Web3 technologies. By offering an avenue for assessing AI agent capabilities, AIxCrypto positions itself as a pioneer in developing AI solutions that can seamlessly interact with decentralized networks.
The remarkable growth of AIxCrypto's user base highlights the company's accelerating momentum within the space. As of February 2026, the company reports more than 4.8 million registered wallet addresses, with a notable figure of 3.7 million users accumulating utility points. This increase embodies a staggering 336% month-over-month growth, underscoring robust user engagement metrics. Community interaction is strong, as evidenced by 198,000 linked Twitter accounts, along with 139,000 and 33,000 users on Discord and Telegram, respectively. The active Discord community has expanded to over 59,000 members, illustrating AIxCrypto's flourishing network of engaged participants. This surging interest reflects a compelling need for tools and platforms that facilitate meaningful interaction between AI and blockchain, which AIxC aims to fulfill through its innovative strategies.
Furthermore, the launch of Hub S2 marks another essential development, providing users with enhanced opportunities for AI agent ownership and promoting modular development. This upgrade enables participants to engage in the creation of AI-driven products utilizing user-friendly modular building blocks and natural-language tools. As AIxCrypto continues to simplify access to AI technologies, the company actively paves the way for future products that will focus on AI agents and collaborative frameworks within its evolving Hub ecosystem. Through these advancements, AIxCrypto positions itself at the forefront of blending AI capabilities with blockchain functionalities, further courting a growing user base eager for novel technological integrations.
AIxCrypto’s ambitious expansions not only demonstrate its commitment to innovation but also position the company as a leader in the rapidly changing landscape of AI and blockchain technologies. As it cements its ecosystem further, AIxCrypto aims to deliver solutions that meet the increasingly sophisticated demands of its growing community. The company's continued growth trajectory signals potential opportunities for future collaborations and product innovations that are set to enhance user experience across the platform.
Related Cashu News

CRISPR Therapeutics AG Achieves Financial Progress Amid Advancements in Gene-Editing Portfolio
CRISPR Therapeutics AG (Ticker: UNDEFINED) showcases a pivotal moment in its financial journey with the release of its results for the first quarter of 2026. Highlighting a revenue of $1.46 million, t…

MetaVia to Present Innovative Cardiometabolic Research at 2026 ADA Scientific Sessions
MetaVia is set to showcase its innovative research in cardiometabolic diseases at the upcoming American Diabetes Association (ADA) Scientific Sessions in 2026, following the acceptance of three late-b…

Ionis Pharmaceuticals Advances TRYNGOLZA for Hypertriglyceridemia and Diranersen for Alzheimer's Disease
Ionis Pharmaceuticals has made headlines in the biotechnology sector with the promising potential of its drug TRYNGOLZA, which is designed to treat severe hypertriglyceridemia. During a recent healthc…

ImmunityBio Partners with BCG Laboratory to Enhance Bladder Cancer Treatment Supply and Options
ImmunityBio has secured a critical partnership with Japan's BCG Laboratory to enhance the supply of Bacillus Calmette-Guérin (BCG) in the United States, addressing an urgent need in the treatment of b…